secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPT Therapeutics, Inc. (—)
CIK:        0001673772
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0000950170-25-088715
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

RAPT Therapeutics appoints Scott Braunstein and Ashley Dombkowski to board, expands to 7 directors
--------------------------------------------------------------------------------

- Board expanded from 5 to 7; Drs. Braunstein and Dombkowski appointed as Class III directors with terms expiring at 2028 annual meeting.
- Braunstein brings 30+ years pharma experience; currently operating partner at Aisling Capital, former CEO of Marinus Pharmaceuticals.
- Dombkowski brings over 20 years operating & venture experience; current CEO of Cellics Therapeutics, former CEO of Alladapt Immunotherapeutics.
- Each new director receives initial option grant of 25,000 shares and enters indemnification agreement; compensation policy amended.
- Braunstein appointed to Audit Committee; Dombkowski to Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1673772/000095017025088715/0000950170-25-088715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1673772/000095017025088715/rapt-20250623.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer